Treatment of Overactive Urinary Bladder with Oxybutinin Improves Quality of Life and Urodynamic Parameters in Multiple Sclerosis
DOI:
https://doi.org/10.5457/ams.v41i2.298Keywords:
Multiple sclerosis, Oxybutinin, Over active bladderAbstract
Background. The most common voiding disturbance in patients with multiple sclerosis is a spastic bladder or overactive bladder.
Aim. To evaluate the efficiency of the therapy with oxybutinin on urodynamic parameters and the quality of life of patients with an overactive bladder in multiple sclerosis.
Patients and Methods. This was the cross-over study that tested the efficiency of oxybutinin tablets prescribed in a daily dose of 2x5 mg. Urodynamic testing and the quality of life questionnaires were filled out before and after the treatment with oxybutinin for 3 months. Urodynamic parameters included the first detrusor contraction, maximum capacity, number of daily and night micturition, and the number of daily and night incontinence.
Results. There were 30 patients enrolled. Questionnaires' scores of symptoms before and after treatment were 62 ±15 and 32±15, respectively (< 0,0001). Questionnaires' scores of quality of life before and after treatment were 28±14 and 56±15, respectively (< 0,0001). The first detrusor contraction improved from 79,6±43,7 ml to 131±62,7 (p<0,0001), maximal capacity from 223,2±68,9, to 317,3±101,1 ml (p<0,0001). Daily micturition number decreased from 13,3±4,7 to 7,05±2,2 (p<0,0001), night micturition number from 3,5 to 2 (p<0,0001). Daily incontinence number decreased from 2,6±1,9 to 1,1±1,2(p<0,0001), night incontinence number from 1 to 0 (p=0,0002). The side effects of the therapy were found in 35% of patients as dryness in the mouth, which did not require interruption of therapy.
Conclusion. Our results showed that the treatment of an overactive bladder with Oxybutinin of 2x5 mg. doses, improved the quality of life and urodynamic parameters in patients with multiple sclerosis.
Keywords. Multiple sclerosis – Oxybutinin- Over active bladder
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
